IL6 and renal cell carcinoma: In a clinical dataset that included 95 RCC patients, higher expression levels of lncRNA SRLR were associated with reduced progression-free survival (PFS) (HR = 0.407, 95%CI = 0.222–0.744, p = 0.003) and was additionally related to low benefit to treatment with sorafenib, and high levels of IL-6 [15].